| Autor: |
Mahalingam VD; 1 Department of Molecular and Integrative Physiology, University of Michigan , Ann Arbor, Michigan., Behbahani-Nejad N, Horine SV, Olsen TJ, Smietana MJ, Wojtys EM, Wellik DM, Arruda EM, Larkin LM |
| Jazyk: |
angličtina |
| Zdroj: |
Tissue engineering. Part A [Tissue Eng Part A] 2015 Mar; Vol. 21 (5-6), pp. 1047-54. Date of Electronic Publication: 2015 Jan 08. |
| DOI: |
10.1089/ten.TEA.2014.0422 |
| Abstrakt: |
The use of autografts versus allografts for anterior cruciate ligament (ACL) reconstruction is controversial. The current popular options for ACL reconstruction are patellar tendon or hamstring autografts, yet advances in allograft technologies have made allogeneic grafts a favorable option for repair tissue. Despite this, the mismatched biomechanical properties and risk of osteoarthritis resulting from the current graft technologies have prompted the investigation of new tissue sources for ACL reconstruction. Previous work by our lab has demonstrated that tissue-engineered bone-ligament-bone (BLB) constructs generated from an allogeneic cell source develop structural and functional properties similar to those of native ACL and vascular and neural structures that exceed those of autologous patellar tendon grafts. In this study, we investigated the effectiveness of our tissue-engineered ligament constructs fabricated from autologous versus allogeneic cell sources. Our preliminary results demonstrate that 6 months postimplantation, our tissue-engineered auto- and allogeneic BLB grafts show similar histological and mechanical outcomes indicating that the autologous grafts are a viable option for ACL reconstruction. These data indicate that our tissue-engineered autologous ligament graft could be used in clinical situations where immune rejection and disease transmission may preclude allograft use. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
